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Abstract: Hypertension is a global condition affecting billions worldwide. It is a signiﬁ  cant 
contributor to cardiovascular events, cardiac death and kidney disease. A number of medication 
classes exist to aid healthcare providers and their patients in controlling hypertension. Nifedipine, 
a dihydropyridine calcium channel blocker, was once one of the most widely used medications 
for hypertension, but safety and tolerability concerns along with the introduction of new classes 
of antihypertensive medications and an increasing pool of data showing mortality beneﬁ  t of 
other classes caused nifedipine to fall out of favor. More recently, long-acting formulations were 
developed and made available to clinicians. These newer formulations were designed to address 
many of the concerns raised by earlier formulations of nifedipine. Numerous clinical trials have 
been conducted comparing long-acting nifedipine to many of the more commonly prescribed 
antihypertensive medications. This review will address the pharmacology, pharmacokinetics 
and the available clinical trial data on long-acting nifedipine and summarize its role in the 
management of hypertension.
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Introduction
Hypertension is a progressive disease that affects more than 1 billion people around the 
world (Chobanian et al 2003). The risk of developing hypertension increases with age 
and according to the Framingham Heart Study, even those who have a normal blood 
pressure (BP) at the age of 55 still carry a lifetime risk for developing hypertension of 
90% (Vasan et al 2002). Over time, untreated or poorly controlled hypertension can 
lead to acute illness such as myocardial infarction and stroke (Lewington et al 2002). 
Long-standing hypertension is also a risk factor for chronic comorbidities ranging 
from coronary artery disease to kidney disease to left ventricular hypertrophy and 
heart failure (Lewington et al 2002; Rosendorff et al 2007).
American and European guidelines recommend ﬁ  rst-line agents for the treatment 
of hypertension based on the patient’s varying “compelling indications” or comorbid 
disease states (Chobanian et al 2003; Mancia et al 2007). Because several classes of 
medications, such as angiotensin converting enzyme inhibitors (ACEIs) and β-blockers, 
are appropriate for numerous compelling indications their use predominates other classes 
that are less universal, such as calcium channel blockers (CCBs). Dihydropyridine 
CCBs have been determined to be appropriate for ﬁ  rst-line therapy in patients with 
hypertension, particularly in those with left ventricular hypertrophy, asymptomatic 
atherosclerosis, angina pectoris, permanent atrial ﬁ  brillation, peripheral artery disease, 
isolated systolic hypertension, metabolic syndrome, and pregnancy (Lewington et al 
2002; Blood Pressure Lowering Treatment Trialists’ Collaboration 2003; Staessen 
et al 2003; Mancia et al 2007). Non-dihydropyridine CCBs are also appropriate for 
use in patients with angina pectoris and carotid atherosclerosis (Mancia et al 2007). 
One trial found no signiﬁ  cant difference between ACEIs and CCBs in terms of total Vascular Health and Risk Management 2008:4(6) 1250
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number of coronary events, cardiovascular mortality, total 
mortality, or coronary heart disease (Blood Pressure Lowering 
Treatment Trialists’ Collaboration 2003). Extended-release 
calcium channel blockers are recommended as an appropriate 
ﬁ  rst-line agent for the treatment of ischemic heart disease, 
particularly in patients with stable angina pectoris (Chobanian 
et al 2003). Other potential indications include those patients 
at an increased risk for coronary disease and diabetes, 
where CCBs have been shown to reduce the incidence of 
cardiovascular disease and stroke, Raynaud’s syndrome, and 
speciﬁ  c arrhythmias (Chobanian et al 2003). CCBs have not 
been shown to prevent the incidence of heart failure (Blood 
Pressure Lowering Treatment Trialists’ Collaboration 2003). 
African American patients tend to have an increased response 
to CCBs and diuretics as compared to other antihypertensives 
such as ACEIs, angiotensin receptor blockers (ARBs), and 
β-blockers (The ALLHAT Ofﬁ  cers and Coordinators for 
the ALLHAT Collaborative Research Group 2002). It is 
important to note that not all CCBs are alike and in fact this 
class is more heterogenous than most other classes of anti-
hypertensives therefore each agent needs to be considered 
individually.
Nifedipine is a dihydropyridine calcium channel blocker, 
the short acting formulation of which has been associated 
with reﬂ  ex sympathetic nervous system (SNS) activation 
leading to ﬂ  ushing, tachycardia, worsening myocardial 
ischemia, and cerebrovascular ischemia; therefore only 
longer acting formulations should be used (Gibbons et al 
2003). Numerous extended-release formulations are 
available worldwide and have been shown to be equally 
efﬁ  cacious as compared to other antihypertensives such 
as ARBs, β-blockers, and diuretics in the management of 
hypertension (Frishman et al 1987; Weir et al 1996; Brown 
et al 2000). This review focuses on the extended-release 
formulations of nifedipine and their role in the treatment of 
patients with hypertension.
Pharmacology
Nifedipine exerts its effect in hypertension, as well as angina, 
by acting as an arterial vasodilator. Calcium ions regulate 
smooth muscle contractions contributing to inotropic and 
chronotropic activity in the heart (Rosendorff et al 2007). 
The L-type channels in vascular smooth muscle permit 
the entrance of calcium ions which potentiates a contrac-
tion (Abernathy et al 1999). Dihidropyridine CCBs such 
as nifedipine bind to the L-type channel in arterial tissue, 
particularly coronary arteries, preventing the influx of 
calcium ions which allows for vasodilation, thus increasing 
myocardial oxygen supply (Abrams et al 2001; Pﬁ  zer 2003). 
Myocardial oxygen demand is reduced with the decrease in 
peripheral vascular resistance (Abrams et al 2001). CCBs 
are also responsible for a decrease in afterload, illustrated 
by a decrease in systolic BP (SBP) (Abrams et al 2001). 
The decrease in BP depends on the baseline value such that 
patients with a higher BP will experience a more signiﬁ  cant 
reduction (Frishman et al 1989). Several studies have also 
shown a decrease in the development of new atherosclerotic 
lesions with the use of dihydropyridine CCBs which is 
attributed to their vascular protective characteristics (Wenzel 
et al 1997).
Pharmacokinetics
Nifedipine displays zero-order kinetics across the dosing 
range from 30 mg to 180 mg with an estimated elimina-
tion half-life of 1.7 hours. This is signiﬁ  cant considering 
the effect on heart rate (HR) and BP corresponds to plasma 
drug concentration (Swanson et al 1987; Pﬁ  zer 2003). Renal 
impairment does not affect the half-life of nifedipine unless it 
is severe (CrCl   25 mL/minute), in which case the half-life 
is extended to approximately 3.8 hours (Chung et al 1987). 
Sixty to eighty percent of the dose is excreted as an inactive 
metabolite in the urine (Pﬁ  zer 2003). Nifedipine is hepati-
cally metabolized and is 92% to 98% protein bound. Due to 
signiﬁ  cant ﬁ  rst-pass metabolism nifedipine’s bioavailabil-
ity is between 45%–68% (Chung et al 1987; Pﬁ  zer 2003). 
Chronic liver disease may prolong the disposition half-life 
and increase the bioavailability (Pﬁ  zer 2003).
Extended-release formulations of nifedipine are desired in 
order to prolong the therapeutic effect and prevent reﬂ  ex SNS 
activation. The nifedipine gastrointestinal therapeutic system 
(GITS) is one of the more prevalent extended-release formu-
lations. There are two layers in the system; the top contains 
drug and osmotic agent and the bottom containing an osmotic 
driving agent only (Chung et al 1987; Swanson et al 1987). 
Both layers take water in across the membrane via osmosis 
creating a suspension within the top layer (Swanson et al 
1987). This suspension is driven out through a pre-drilled 
hole as the osmotic layer expands (Swanson et al 1987). 
The rate at which drug disperses corresponds to the rate at 
which water enters the system; generally speaking, drug is 
released consistently over 16 to 18 hours with a bioavailabil-
ity between 75% and 85% at steady state (Chung et al 1987; 
Swanson et al 1987). The diameter of the pre-drilled opening 
limits the rate at which drug exits the system, thus prevent-
ing a dose-dumping effect (Swanson et al 1987; Chung et al 
1987). This process does not depend upon pH or intestinal Vascular Health and Risk Management 2008:4(6) 1251
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motility, therefore drug distribution out of the system does 
not vary with gastrointestinal contents or function (Swanson 
et al 1987). The exception occurs when retention time in the 
gut is extensively minimized to less than 24 hours, such as 
with short bowel syndrome, in which case the full dose is 
not absorbed (Chung et al 1987).
Studies have been conducted that compare various 
nifedipine formulations in an attempt to establish if there 
is a clinically signiﬁ  cant beneﬁ  t of one extended-release 
formulation over another. It has been established that the reﬂ  ex 
activation of the SNS correlates with the rate of increase in 
plasma drug levels. Thus it is hypothesized that a more gradual 
rise in drug concentrations should decrease SNS activation, 
in turn reducing adverse events associated with short acting 
nifedipine (Fogari et al 2003). One such trial of 25 patients 
compared nifedipine GITS 60 mg once daily (Adalat XL®; 
Bayer) to either nifedipine prolonged action 20 mg twice 
daily (Adalat PA®) or two 10 mg nifedipine capsules every 
8 hours (Adalat®) under fasting conditions (Toal et al 2004). 
This trial failed to demonstrate a relationship between peak 
plasma drug concentrations with the three formulations and 
BP reduction, which opposes the ﬁ  ndings of previous studies 
(Toal et al 2004). The author concluded that patients should 
not be switched between formulations because although there 
was no correlation with BP, peak plasma drug concentrations 
may correspond to reﬂ  ex activation of the SNS, thus inducing 
cardiovascular events (Toal et al 2004).
Due to the high incidence of tachycardia and vasodilatory 
symptoms associated with short-acting nifedipine, emphasis 
has been placed on determining the effect of extended-release 
nifedipine on catecholamine levels and corresponding HR 
and BP values. It has been suggested that a higher incidence 
of cardiovascular events associated with nifedipine may be 
due to reﬂ  ex activation of the SNS (Champlain et al 1998). 
As long-acting nifedipine formulations became more readily 
available attention was placed on the occurrence of reﬂ  ex 
SNS activation in correlation with plasma drug concentra-
tion (Champlain et al 1998). One study compared the acute 
and chronic effects of nifedipine on HR, BP, norepinephrine 
(NE), and epinephrine levels (Champlain et al 1998). Sixty-
ﬁ  ve patients with mild to moderate hypertension were treated 
with nifedipine retard 10 mg twice daily, nifedipine GITS 
30 mg daily, or amlodipine 5 mg daily for 2 weeks with the 
option to double treatment doses for the last 4 weeks if BP 
was not controlled (Champlain et al 1998). Acute treatment 
effects were assessed just before and after the ﬁ  rst treatment 
dose whereas chronic effects were analyzed after 6 weeks 
of therapy (Champlain et al 1998). All three treatment arms 
signiﬁ  cantly reduced SBP and diastolic BP (DBP) at 2 weeks 
through the end of the treatment period, but only amlodipine 
was found to increase HR signiﬁ  cantly by the end of therapy 
(75 ± 2 beats per min to 81 ± 2.3 beats per minute, p   0.05). 
While all three treatments equally reduced BP, their effects 
on norepinephrine levels were not equivalent. Plasma norepi-
nephrine levels increased signiﬁ  cantly with nifedipine retard, 
both acutely and chronically, reaching their peak 3 hours 
after drug administration (Champlain et al 1998). Similarly, 
chronic amlodipine therapy increased plasma levels of nor-
epinephrine by 50% compared to baseline (Champlain et al 
1998). Chronic therapy with nifedipine GITS decreased 
plasma NE levels signiﬁ  cantly 6 hours after the dose and 
this effect was maintained throughout the dosing interval 
(Champlain et al 1998). The nifedipine GITS formulation 
was associated with a more gradual decrease in BP without 
an increase in NE, potentially due to the fact that plasma 
drug levels were lower than those obtained by nifedipine 
retard (Champlain et al 1998). This study demonstrated a 
relationship between an increase in plasma norepinephrine, 
the rate of increase in drug concentration, and a subsequent 
and sudden drop in BP (Champlain et al 1998).
Another, 48-week study compared nifedipine GITS to 
lercanidipine, a third generation CCB whose lipophilicity 
allows for a longer half-life (Fogari et al 2003). Patients were 
randomized to 10 mg of lercanidipine or 30 mg of nifedipine 
GITS for 4 weeks, after which the doses could be doubled if 
the patient’s DBP was   90 mmHg (Fogari et al 2003). BP, 
HR, and NE levels were evaluated throughout the study period 
(Fogari et al 2003). Compared to placebo, both treatments 
effectively decreased BP (p   0.001 for both arms) with no sig-
niﬁ  cant change in HR (Fogari et al 2003). There was a signiﬁ  -
cant increase in NE concentrations at 4 weeks in both treatment 
arms (Fogari et al 2003). Only nifedipine GITS signiﬁ  cantly 
increased NE levels at 48 weeks compared to baseline drug 
concentrations reached their peak and 12 hours after the dose 
(p   0.05 at both times) (Fogari et al 2003). Because HR was 
not affected despite changes in NE, this suggests the effects of 
nifedipine GITS on the SNS might be selective for peripheral 
and not cardiac nerves (Fogari et al 2003). Just as BP control 
is a predictor for cardiovascular events, norepinephrine levels 
are a similar surrogate marker; therefore, because both agents 
decreased BP effectively, little can be extrapolated from the 
variation in effect on norepinephrine.
Clinical trials
Nifedipine has been compared head-to-head with several other 
antihypertensives, particularly when the GITS formulation Vascular Health and Risk Management 2008:4(6) 1252
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was released. With a diminished concern for reﬂ  ex SNS 
activation nifedipine had the potential to play a larger role in 
the management of hypertension. In a 10-week, multi-center, 
double-blind study of 102 participants, patients received nife-
dipine GITS 30 or 60 mg daily, hydrochlorothiazide (HCTZ) 
25 or 50 mg daily, or placebo (Gavras et al 1987). The major-
ity of patients in the active treatment arms ﬁ  nished the study 
on 50 mg of HCTZ or 60 mg of nifedipine GITS (Gavras 
et al 1987). Both treatments were signiﬁ  cantly better than 
placebo in decreasing SBP and DBP with 71% of the HCTZ 
group and 67% of the nifedipine group achieving a sitting 
DBP   90 mmHg (Gavras et al 1987). The authors concluded 
that nifedipine GITS monotherapy decreases BP with efﬁ  cacy 
similar to that of HCTZ (Gavras et al 1987).
In another double-blind study, patients received nife-
dipine GITS or sustained-release propranolol for 8 weeks, 
both of which could be titrated to an optimal dose if the 
DBP remained  90 mmHg (Frishman et al 1989). The main 
objective of the trial was to evaluate the change in BP from 
baseline as well as the proportion of patients whose BP was 
decreased to goal (Frishman et al 1989). The majority of 
patients in the nifedipine and propranolol groups ended the 
trial on 90 mg and 240 mg daily, respectively (Frishman et al 
1989). In this study, sitting SBP was decreased a mean of 
15.9 mmHg in the nifedipine group compared to 5.7 mmHg 
in the propranolol group (p   0.001) (Frishman et al 1989); 
sitting DBP was reduced by a mean of 10 mmHg in the 
nifedipine arm versus 6.1 mmHg in the propranolol group 
(p   0.018) (Frishman et al 1989). Standing SBP was also 
reduced to a greater extent in the nifedipine group (p   0.005) 
(Frishman et al 1989). The proportion of patients receiving 
nifedipine who achieved a goal decrease in sitting and stand-
ing BP was 61% and 52%, respectively, as compared to 25% 
and 28% in the propranolol group (Frishman et al 1989). This 
study showed nifedipine GITS to be more efﬁ  cacious than 
sustained-release propranolol in reducing sitting SBP and 
DBP, as well as standing SBP (Frishman et al 1989).
Nifedipine has also been compared to other dihydropyri-
dine CCBs, such as amlodipine. One particular study random-
ized patients to daily nifedipine GITS 30 mg or amlodipine 
5 mg for 21 weeks to assess the effect on DBP as well as 
quality of life (Testa et al 1998). The main objectives of the 
study were to evaluate the change in SBP and DBP as well as 
the change in health-related quality of life. Results pertaining 
to quality of life will be discussed later (see Tolerability). The 
study showed no signiﬁ  cant difference between treatment 
arms with respect to SBP or DBP (Testa et al 1998). The 
mean decrease in SBP was 18.8 mmHg with nifedipine and 
19.7 with amlodipine while the mean reduction in DBP was 
15.5 with nifedipine and 15.7 with amlodipine (p   0.55 for 
SBP and DBP) (Testa et al 1998).
As mentioned previously, ACEIs are recommended as 
ﬁ  rst-line antihypertensives in patients with varying comorbid 
conditions. One study compared the efﬁ  cacy of once-daily 
nifedipine GITS 30 to 60 mg with that of enalapril 5 to 10 mg 
daily over the course of 8 weeks by measuring BP and HR 
at each visit as well as utilizing ambulatory BP monitoring 
(ABPM) (Schulte et al 2000). At the end of the treatment 
period DBP and SBP were signiﬁ  cantly decreased from base-
line in both groups (p   0.001 for DBP in both treatments) 
(Schulte et al 2000). More patients in the nifedipine group were 
maintained on a low-dose regimen compared to the enalapril 
group (p   0.05) (Schulte et al 2000). Twenty-four hour SBP 
decreased from 141 ± 15 mmHg to 134  ± 14 mmHg in the nife-
dipine group compared to enalapril where SBP decreased from 
140 ± 15 mmHg to 131 ± 15 mmHg (Schulte et al 2000). DBP 
was 86 ± 9 mmHg for both groups at baseline and decreased to 
82 ± 9 mmHg in the nifedipine group and 80 ± 8 mmHg in the 
enalapril group (Schulte et al 2000). This trial demonstrated 
that nifedipine GITS and enalapril are similarly efﬁ  cacious for 
the treatment of hypertension (Schulte et al 2000).
ARBs are a standard ﬁ  rst-line therapy and alternative to 
ACEIs in the treatment of hypertension, particularly in those 
patients with compelling indications such as diabetes, chronic 
kidney disease, and heart failure (Chobanian et al 2003). One 
trial sought to compare the effects of nifedipine GITS 30 mg, 
60 mg, or 90 mg with losartan 50 mg monotherapy or with 
HCTZ 12.5 mg or 25 mg on mean sitting DBP after 12 weeks 
(Weir et al 1996). Two hundred twenty-three patients were 
treated and decreases in BP were similar in both groups (Weir 
et al 1996). Those patients who had a higher baseline DBP 
(106–115 mmHg) showed a signiﬁ  cantly greater beneﬁ  t for 
sitting DBP at the end of therapy when treated with losartan 
compared with nifedipine GITS (–16.2 ± 7.1 mmHg, p = 0.03) 
(Weir et al 1996). There was no signiﬁ  cant difference in SBP, 
the percentage of patients who had a sitting DBP   90 mmHg 
at the end of treatment, HR, quality of life, or adverse events 
between the two groups (Weir et al 1996). The authors 
concluded that losartan is similarly efﬁ  cacious to nifedipine 
GITS in the treatment of hypertension but with greater toler-
ability, particularly with respect to edema (Weir et al 1996). 
Similar results were found in an open-label study comparing 
nifedipine GITS to telmisartan in combination with HCTZ 
(Fogari et al 2005).
It has been well demonstrated that short-acting nifedipine 
can cause reﬂ  ex sympathetic activation. What has been less Vascular Health and Risk Management 2008:4(6) 1253
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studied is how extended-release nifedipine affects the SNS. 
Several trials have evaluated the effects of extended-release 
nifedipine on HR and BP throughout the dosing interval. 
A study by Wenzel and colleagues evaluated the effect of 
nifedipine GITS 60 mg on muscle sympathetic nervous 
activity (MSA) as compared to short-acting nifedipine 5 mg 
and 10 mg or placebo in normotensive patients (Wenzel 
et al 1997). MSA, measured in change of bursts per minute, 
increased signiﬁ  cantly following 10 mg of short-acting nife-
dipine and 60 mg nifedipine GITS (p   0.05 vs placebo). 
There was no signiﬁ  cant change in HR in the nifedipine GITS 
group compared to baseline; however during the cold pres-
sor test HR increased signiﬁ  cantly (p   0.05). SBP did not 
change but DBP increased signiﬁ  cantly following the admin-
istration of nifedipine GITS (p   0.05). Because plasma NE 
levels are a predictor of mortality in heart failure patients and 
elevated levels may be harmful in patients with hypertension, 
concentrations were evaluated at various time points in this 
trial. Concentrations increased signiﬁ  cantly 150 minutes after 
drug administration (p   0.05) but plasma epinephrine levels 
did not change signiﬁ  cantly. Plasma endothelin levels were 
signiﬁ  cantly elevated in the nifedipine GITS group 6 hours 
after drug intake (p   0.05). This trial showed that nifedip-
ine stimulates peripheral sympathetic nerve activity, despite 
the formulation of the drug; however there was no change 
in cardiac sympathetic activity. It is proposed that because 
extended-release nifedipine allows for a more controlled 
onset of vasodilation, the SNS is selectively activated in the 
periphery leading to an increase in MSA while the cardiac 
sympathetic system is not affected as demonstrated by the 
lack of change in HR (Wenzel et al 1997). A similar theory 
has been proposed in previously discussed studies (Fogari 
et al 2003).
Other cardiovascular pathways are implicated in the pro-
gression of hypertension and nifedipine may have beneﬁ  ts 
beyond its vasodilatory effects. There are several mecha-
nistic factors involving granulocyte-macrophage colony-
stimulating factor (GM-CSF) and tumor necrosis factor-α 
(TNF-α). GM-CSF and TNF-α are increased in patients with 
hypertension and this may contribute to an increased risk for 
atherosclerosis (Shima et al 2008). These details have just 
recently been elucidated in a trial that evaluated the effects 
of CCBs on superoxide (O2
−) liberation from neutrophils. 
O2
− release is mediated by GM-CSF and TNF-α and studies 
have shown that some CCBs may inhibit this process (Shima 
et al 2008). O2
− release mediated by TNF-α was suppressed 
signiﬁ  cantly by nifedipine (p   0.01) (Shima et al 2008). The 
authors of this trial suggest that some CCBs may have a role 
in the prevention of atherosclerosis via the suppression of 
neutrophil activation (Shima et al 2008). One should keep in 
mind that this study looked at several surrogate endpoints for 
atherosclerosis in vitro, therefore the clinical signiﬁ  cance is 
unknown. As this is a relatively new area of study more data 
are needed before the effects of nifedipine on atherosclerosis 
can be substantiated.
All of these trials share similar limitations in that their 
duration of treatment and follow-up is relatively short, rang-
ing from 8 to 48 weeks (Frishman et al 1989; Schulte et al 
2000; Fogari et al 2003). The mean age of patients in the 
previously mentioned studies ranges between the sixth and 
seventh decades of life; therefore most of these patients can 
expect to live another 20 to 30 years (Mancia et al 2007). 
Patients were followed for just a few months despite the fact 
that complications from poorly controlled hypertension take 
years to manifest. Ultimately it is the occurrence of an event, 
whether fatal or non-fatal, that is of interest, not the surrogate 
endpoints such as changes in BP from baseline. While it is 
well understood that BP is a strong predictor of cardiovas-
cular events, the duration of follow up may not be adequate 
to determine a truly beneﬁ  cial effect, or lack thereof.
A prospective, double-blind trial by Brown and 
colleagues assessed morbidity and mortality in European and 
Israeli patients who had hypertension in addition to a car-
diovascular risk factor such as hypercholesterolemia, CHD, 
peripheral vascular disease, left ventricular hypertrophy, 
or a family history of myocardial infarction (Brown et al 
2000). The primary endpoint of the International Nifedipine 
GITS Study: Intervention as a Goal in Hypertension Treat-
ment (INSIGHT) trial was the composite of death from a 
cardiovascular or cerebrovascular cause, non-fatal stroke, 
myocardial infarction, and heart failure. Patients were ran-
domized to receive nifedipine GITS 30 mg or co-amilozide 
(HCTZ 25 mg/amiloride 2.5 mg) daily (Brown et al 2000). 
The primary outcome was reported in 6.3% of patients in 
the nifedipine group compared to 5.8% in the co-amilozide 
group (p = 0.34). There was no signiﬁ  cant difference in 
event rates between groups. Signiﬁ  cantly greater number of 
patients experienced a fatal myocardial infarction or non-
fatal heart failure in the nifedipine group (0.5% vs 0.2%, 
p = 0.017 and 0.8% vs 0.3%, p = 0.028, respectively). The 
authors concluded that both agents were equally efﬁ  cacious 
in preventing cardiovascular and cerebrovascular complica-
tions (Brown et al 2000).
One subanalysis of the INSIGHT data was performed 
to evaluate ambulatory BP values before and after treat-
ment (Mancia et al 2002). Ofﬁ  ce and 24-hour average SBP, Vascular Health and Risk Management 2008:4(6) 1254
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DBP, and pulse pressure were signiﬁ  cantly reduced by both 
treatments. The authors therefore concluded that nifedipine 
and diuretics offer similar protection against cardiovascular 
events (Mancia et al 2002). Another subanalysis evaluated 
outcomes in patients with isolated systolic hypertension 
(ISH) (Mancia et al 2004). Primary outcomes occurred in 
6% of patients in the nifedipine arm compared to 6.6% in 
the group receiving diuretics (p = 0.67) (Mancia et al 2004). 
There were no signiﬁ  cant differences in the composite end-
point between those patients with ISH compared to non-ISH 
patients (Mancia et al 2004). According to logistic regression 
analyses ISH was not found to be a predictor of the composite 
primary outcomes after adjusting for baseline characteristics 
(Mancia et al 2004). The study’s authors determined that 
nifedipine GITS and diuretics are equally efﬁ  cacious in the 
treatment of patients with ISH (Mancia et al 2004).
Chronotherapy
It has been well documented that HR and BP vary throughout 
the day in a circadian pattern and one hypothesis suggests 
the daily increases in HR and BP correspond to a recurrent 
rise in norepinephrine. This theory is supported by the fact 
that the incidence of ischemic events such as myocardial 
infarctions and stroke is highest in the morning. Numerous 
studies have evaluated the correlation between the time of 
day extended-release nifedipine is administered with NE 
levels and subsequent cardiovascular events (White et al 
1998; Hermida et al 2007; Hermida et al 2008).
One double-blind, randomized, parallel-group trial of 
557 patients compared controlled-onset extended-release 
(COER) verapamil 180 mg taken at bedtime with nifedipine 
GITS 30 mg taken in the morning for a maximum of 10 weeks 
(White et al 1998). Doses were increased in a step-wise 
fashion to a goal SBP   140 mmHg and DBP   90 mmHg 
(White et al 1998). The mean doses of nifedipine GITS and 
COER-verapamil at the end of the trial were 64 mg and 
314 mg, respectively (White et al 1998). The primary efﬁ  -
cacy endpoint was the change in BP from baseline following 
four weeks of a consistent treatment dose (White et al 1998). 
Therapies were determined to be equal if the mean change 
from baseline was  5 mmHg for SBP and  3 mmHg for 
DBP (White et al 1998). After 10 weeks of treatment there 
was no signiﬁ  cant difference in the mean change of early 
morning BP between treatment arms. There was a statisti-
cally signiﬁ  cant difference in early morning HR between the 
two therapies (p   0.001), however the clinical signiﬁ  cance 
of the 4 beats/minute decrease with COER–verapamil as 
compared to the 2 beats per minute increase with nifedipine 
GITS is minimal. The rate of rise in BP and HR in the early 
morning may be one of the more predictive factors in relation 
to cardiovascular events. This trial demonstrated that both 
therapies decreased the rate of increase in BP compared to 
baseline; however nifedipine GITS increased the rate of rise 
in HR while COER–verapamil signiﬁ  cantly decreased the 
rate of rise in HR (p   0.001) (White et al 1998). The early 
morning HR-SBP product, an index of myocardial oxygen 
demand, was calculated after 4 and 10 weeks of treatment 
and showed that COER–verapamil signiﬁ  cantly decreased 
the HR-SBP product compared with nifedipine GITS at 4 and 
10 weeks (p  0.0001 and p = 0.0003, respectively). The 
greatest extent of lowering by COER–verapamil was between 
4:00 AM and 8:00 PM. The largest difference occurred 
between 6:00 AM and 6:00 PM; the smallest difference 
was found between 10:00 PM and 4:00 AM. Twenty-four 
hour ambulatory BP values were also monitored after 4 and 
10 weeks of therapy. Recordings demonstrated that 24 hour 
mean awake and sleep DBP were similar between groups 
(White et al 1998). This trial attempted to dose nifedipine 
GITS and COER–verapamil in a manner so that peak drug 
concentrations would be achieved at the time when BP and 
HR peak the most rapidly, in the early morning; however 
there was no significant difference in mean change in 
morning BP between groups (White et al 1998).
When 30 mg of nifedipine GITS was administered to 
a small patient population there was no difference in the 
antihypertensive effect of the medication during the day or 
at night (Hermida et al 2007). A larger randomized, prospec-
tive, open-label trial of 80 patients was then conducted to 
determine if nifedipine GITS 30 mg or 60 mg given ﬁ  rst thing 
in the morning or at bedtime would have varying effects on 
BP’s circadian pattern over the course of 16 weeks (Hermida 
et al 2007). BP was measured over 48 hours via ABPM (Her-
mida et al 2007). The results showed that when nifedipine 
GITS 30 mg was administered in the morning or at bedtime 
there was a signiﬁ  cant decrease in 24-hour BP compared 
with baseline (p   0.001 for both regimens) (Hermida et al 
2007). There was no effect on HR or the circadian pattern 
of BP, including maximum BP readings throughout the 
24-hour interval with either dosing strategy (Hermida et al 
2007). In comparison, when 60 mg doses of nifedipine GITS 
were administered, there was a signiﬁ  cant beneﬁ  t to bedtime 
dosing in relation to mean 24-hour BP control (p   0.001) 
(Hermida et al 2007). Additionally, patients who received 
nifedipine GITS at bedtime reported signiﬁ  cantly less edema 
than those who received the drug ﬁ  rst thing in the morning 
(p = 0.026) (Hermida et al 2007). This trial demonstrated Vascular Health and Risk Management 2008:4(6) 1255
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that the efﬁ  cacy of nifedipine GITS is independent of the 
time of day at which it is administered; however there is a 
dose-dependent relationship relative to the drug’s efﬁ  cacy 
and safety with bedtime dosing as compared to early morning 
administration (Hermida et al 2007).
Another study by some of the same authors as the 
previously mentioned trial studied patients with hypertension 
who received nifedipine GITS 30 mg daily either ﬁ  rst thing 
in the morning or at bedtime for eight weeks (Hermida et al 
2008). Because the earlier study showed a slight beneﬁ  t in bed-
time dosing, this theory was investigated further using ABPM 
(Hermida et al 2008). Both SBP and DBP were signiﬁ  cantly 
decreased with bedtime dosing as compared to morning dosing 
(SBP p = 0.01, DBP p   0.001). Morning administration still 
decreased SBP and DBP signiﬁ  cantly compared to baseline 
values (Hermida et al 2008). Asleep mean SBP, morning surge 
of SBP, and asleep mean DBP were signiﬁ  cantly decreased 
with bedtime dosing as compared to morning dosing (Hermida 
et al 2008). The authors of this study concluded that bedtime 
administration of nifedipine GITS signiﬁ  cantly improves 
ambulatory BP and the prevalence of edema compared to 
morning dosing (Hermida et al 2008).
Tolerability
Extended-release nifedipine appears to be relatively well 
tolerated, particularly compared with other antihypertensives, 
because it does not cause depression of the central nervous 
system or orthostasis (Gavras et al 1987). Common adverse 
events mentioned in the literature are summarized in Table 1. 
The most signiﬁ  cant adverse effect, edema, is dose related 
and occurs in 10% to 30% of patients who are receiving 
180 mg (Pfizer 2003). When compared with placebo, 
headache and edema were more common in the nifedipine 
extended-release group (Pﬁ  zer 2003).
When nifedipine GITS was compared with COER–
verapamil the overall incidence of adverse effects was 
similar between groups (74% and 68%, respectively) (White 
et al 1998). Peripheral edema (22% vs 4%, p   0.001) and 
arthralgias (6% vs 2%, p = 0.048) were reported signiﬁ  cantly 
more often in the nifedipine GITS group compared to the 
COER–verapamil group (White et al 1998). When the GITS 
formulation was compared to prolonged action and capsule 
formulations nifedipine GITS was better tolerated with 
respect to overall adverse events, particularly headache and 
dizziness (Toal et al 2004). Only vomiting was more common 
in the nifedipine GITS arm compared to the other formula-
tions (Toal et al 2004).
Nifedipine GITS was not as well tolerated as losartan/HCTZ 
or telmisartan/HCTZ in 12 week studies (Weir et al 1996; 
Fogari et al 2005). More patients in the nifedipine group with-
drew from the study as compared to the losartan/HCTZ group 
(19% vs 7%, p = 0.012) (Weir et al 1996). The most common 
Table 1 Incidence of adverse events reported in clinical trials




Toal et al 
2004
(60 mg/day)
Pﬁ  zer 2003
180 mg/day
Fogari et al 
2005
60 mg/day
Weir et al 
1996
30, 60, or 
90 mg/day
Testa et al 
1998
30 mg/day
Overall incidence 74% 24% 61%
Peripheral edema 22% 10%–30% 13.8% 12% 24.2%
Constipation 8% 3.3%
Arthralgia 6%  3%
Back pain 1%  1%
Headache 21% 15.8% 5.2% 12% 12.4%
Dizziness 3% 4.1% 1.7% 1%
Nausea 3% 3.3% 1.7%
Vomiting 7%  1%
Increased alk phos 5.4%
Fatigue 5.9% – 2%
Polyuria  3% 1.7%
Rash erythematosus  3% 1.7%
Flushing  3% 5.2% 8.4%
Palpitation  3% 3.4%
Pruritus  3% 1.7%Vascular Health and Risk Management 2008:4(6) 1256
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cause of withdrawal from the study was edema which was 
signiﬁ  cantly more common in the nifedipine group than in those 
receiving losartan (p = 0.005) (Weir et al 1996). Ankle edema 
(13.8% vs 1.6%), headache (5.2% vs 0%), dizziness (1.7% 
vs 0%), polyuria (1.7% vs 0%), rash erythematosus (1.7% vs 
0%), ﬂ  ushing (5.2% vs 0%), palpitation (3.4% vs 0%), and 
pruritus (1.7% vs 0%) were all more common in the nifedipine 
group compared to telmisartan–HCTZ (Fogari et al 2005).
Quality of life has been assessed in patients on different 
dihydropyridine CCBs. One such study investigated the change 
in quality of life from baseline assessed by the distress of side 
effects and symptoms of patients receiving either nifedipine 
GITS 30 mg or amlodipine 5 mg daily (Testa et al 1998). 
Patients were assessed using the Higher Symptom Distress 
Index score where higher scores were indicative of more 
distress (Testa et al 1998). Mean quality of life scores were 
comparable between groups at baseline (Testa et al 1998). 
Lower extremity edema (24.2% vs 17.4%), ﬂ  ushing (8.4% 
vs 10.7%), and headache (12.4% vs 11.2%) were reported 
in  5% of patients receiving either nifedipine or amlodipine 
with no difference between groups (Testa et al 1998). Fifteen 
percent of patients receiving nifedipine and 14% of patients 
receiving amlodipine withdrew before the study’s completion 
due to adverse events (Testa et al 1998). Patients treated with 
nifedipine had more distress secondary to shortness of breath, 
constipation, and tachycardia as opposed to the amlodipine 
arm which had more distress as a result of thirst and loss of 
taste (Testa et al 1998). The Mental/Emotional Health scale 
improved signiﬁ  cantly (p = 0.012) from baseline in patients 
receiving nifedipine (Testa et al 1998). The Psychological 
Distress scale (p = 0.021), Anxiety subscale (p = 0.012), and 
Depression subscale (p = 0.071) also improved from baseline; 
however the Depression subscale did not improve signiﬁ  -
cantly (Testa et al 1998). In the amlodipine group, signiﬁ  cant 
improvements were seen in the Mental/Emotional Health 
scale (p = 0.038), Psychological Well-Being (p = 0.042), and 
General Positive Affect subscale (p = 0.037); however there 
was a signiﬁ  cant decrease in the Sexual Symptom Distress 
score (p = 0.045) (Testa et al 1998). In terms of the Quality 
of Life Summary scale, patients receiving nifedipine GITS 
showed a signiﬁ  cant improvement in score (p   0.05) while 
those receiving amlodipine did not change from baseline (Testa 
et al 1998). This trial showed that differences in quality of life 
scores may be attributable to the delivery system.
Conclusion
Clinicians have known for decades that nifedipine is effective 
at lowering BP. However, its use was curtailed when newer 
and seemingly safer options were introduced in the form of 
new drug classes and additional agents within the class of 
dihydropyridine CCBs. In the years that followed, several 
classes of antihypertensives were shown to provide a sig-
niﬁ  cant reduction in morbidity and mortality in high risk 
patients; this propelled these classes of drugs to the forefront 
of hypertension management, speciﬁ  cally ACEIs (Yusuf et al 
2000), ARBs (Dahlof et al 2002), and β-blockers (The Capri-
corn investigators 2001). Thiazide diuretics have also proven 
their utility in managing hypertension patients and are widely 
accepted as a ﬁ  rst-line option in patients devoid of a compel-
ling reason to be prescribed another class of antihypertensive 
(The ALLHAT Ofﬁ  cers and Coordinators for the ALLHAT 
Collaborative Research Group 2002; Chobanian et al 2003). 
Based on the clinical trial data described above, it appears that 
many of the concerns surrounding the older formulations of 
nifedipine have been addressed with the GITS formulation. 
Edema still appears to be relatively common, although timing 
of dosing may ameliorate this effect. While data are not yet 
available for long-term mortality beneﬁ  t of long-acting nife-
dipine, it is reasonable to consider this medication in situations 
where other dihydropyridine CCBs would commonly be used 
(eg, as add-on therapy to improve the patient’s likelihood of 
achieving their BP goal or as initial therapy in patients that 
need general coronary artery disease prevention and do not 
have a compelling reason for prescription of another class of 
antihypertensive). Aggressive use of long-acting nifedipine 
as a ﬁ  rst-line antihypertensive is not supported by clinical 
data or current practice guidelines. A number of clinical 
trials evaluating long-acting nifedipine have recently been 
completed or are ongoing. These include trials evaluating 
the effects of nifedipine on NE, delivery of nifedipine via 
osmotically controlled-release oral delivery system (OROS), 
combination therapy with telmisartan, the effects of nifedipine 
on proteinuria and BP in patients with diabetes, the effect on 
renal function decline and efﬁ  cacy compared with lisinopril. 
The results of these may provide additional insight into the 
most appropriate use of long-acting nifedipine.
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